• Although there have been significant breakthroughs in the Ebola virus disease vaccine development field, there remains an important need for prophylactic anti-Ebola virus vaccine candidates that elicit long-lasting immune responses. (infectiousdiseaseadvisor.com)
  • Therefore, this study designed a novel synthetic anti-Ebola virus glycoprotein DNA vaccine as a strategy to expand protective breadth against diverse Ebola virus strains and evaluated the impact of vaccine dosing and route of administration on protection against lethal Ebola virus-Makona challenge in nonhuman primates. (infectiousdiseaseadvisor.com)
  • The anti-Ebola virus glycoprotein DNA vaccination was delivered in a multiple-injection regimen by intramuscular administration and in a 2-injection regimen by intradermal administration, followed by electroporation. (infectiousdiseaseadvisor.com)
  • Results showed that multiple-injection regimens of the anti-Ebola virus glycoprotein DNA vaccine delivered by intramuscular administration followed by electroporation were 100% protective against the lethal Ebola virus-Makona challenge. (infectiousdiseaseadvisor.com)
  • Of note, when the anti-Ebola virus glycoprotein DNA vaccine was by 2 injections delivered intradermally followed by electroporation, a strong immunogenicity was generated and was also 100% protective against the lethal Ebola virus-Makona challenge. (infectiousdiseaseadvisor.com)
  • Further, although reports of long-term immunogenicity following DNA or other experimental vaccine administration are lacking, results showed that the anti-Ebola virus glycoprotein DNA vaccine induced long-term immune responses in the nonhuman primates. (infectiousdiseaseadvisor.com)
  • The wealth of existing knowledge regarding the design and in vivo pharmacology of these inhibitors may facilitate development of an anti-Ebola-virus therapy. (sciencedaily.com)
  • The proposed research will help to develop potential anti-Ebola virus therapeutics. (sbir.gov)
  • 494-0201-024 Product Overview This product is a recombinant mouse anti-Ebola virus monoclonal antibody. (bioscience-explained.org)
  • In human Ebola virus infection, clinical outcome is strongly associated with the initial innate cytokine response, but the role of NK cells has not been thoroughly examined.METHODSThe novel 2-dose heterologous Adenovirus type 26.ZEBOV (Ad26.ZEBOV) and modified vaccinia Ankara-BN-Filo (MVA-BN-Filo) vaccine regimen is safe and provides specific immunity against Ebola glycoprotein, and is currently in phase 2 and 3 studies. (ox.ac.uk)
  • It is thought that EVD survivors are protected against subsequent infection with EBOV and that neutralising antibodies to the viral surface glycoprotein (GP) are potential correlates of protection. (populationhealthsciences.org)
  • The director of the US National Institute of Allergy and Infectious Diseases (NIAID) has stated that the scientific community is still in the early stages of understanding how infection with the Ebola virus can be treated and prevented. (wikipedia.org)
  • Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. (sciencedaily.com)
  • It has shown an efficacy of 97.5% in preventing infection among 90,000 individuals in an active Ebola virus outbreak in the Democratic Republic of the Congo. (medscape.com)
  • [ 33 ] These findings suggest that early postexposure interferon-beta therapy may be a promising adjunct in the treatment of Ebola virus infection. (medscape.com)
  • Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection. (expasy.org)
  • A single dose of mAb114 fully protects non-human primates five days after lethal Ebola virus infection, and results from a Phase 1 clinical trial of mAb114 indicated the investigational treatment is safe. (nih.gov)
  • How do antibodies protect against infection with Ebola virus? (vhfc.org)
  • This project is to discover and develop small molecule entry inhibitors for Ebola viral infection. (sbir.gov)
  • Using a biomarker of Ebola infection, we've shown that we can detect Ebola infection in the crucial early days after infection. (innovations-report.com)
  • Virologist Yong-Hui Zheng of Michigan State University says the study makes a strong case that CIITA and CD74 mitigate Ebola infection in vitro via cathepsins. (the-scientist.com)
  • But he notes that a 2012 study in mice showed that knocking out cathepsins does not prevent Ebola infection, and he questions the importance of the CIITA/CD74 pathway as a primary antiviral mechanism in animals and humans. (the-scientist.com)
  • In patients who have Ebola virus infection, 2 types of exposure history are recognized: primary and secondary. (medscape.com)
  • This group includes patients who experienced infection with Reston ebolavirus, as evidenced by antibody production, but did not develop Ebola virus disease. (medscape.com)
  • In particular, interaction of LSECtin with the surface glycoproteins of severe acute respiratory syndrome (SARS) coronavirus and Ebola virus has been described, and LSECtin‑mediated infection of cells by Ebola virus has been demonstrated (3, 4). (rndsystems.com)
  • BN-Filo Ebola vaccine regimen (ClinicalTrials.gov, no. bola virus (EBOV) antibodies have been found NCT02509494) ( 2 , 3 ). (cdc.gov)
  • Ebola virus (EBOV) is an enveloped, single-stranded RNA virus that can cause Ebola virus disease (EVD). (populationhealthsciences.org)
  • Ebola virus (EBOV) causes severe hemorrhagic fevers in humans, and no approved therapeutics or vaccine is currently available. (frontiersin.org)
  • Glycoprotein (GP) is the major protective antigen of EBOV, and can generate virus-like particles (VLPs) by co-expression with matrix protein (VP40). (frontiersin.org)
  • Our study indicates that co-expression of GP and VP40 antigens based on the SFV replicon vector generates EBOV VLPs in vitro , and vaccination with recombinant DREP vectors containing GP and VP40 antigens induces Ebola antigen-specific humoral and cellular immune responses in mice. (frontiersin.org)
  • EVD is caused by any one of four pathogenic strains of Ebola virus: Zaire (EBOV), Sudan (SUDV), Taï Forest (TAFV), and Bundibugyo (BDBV). (nature.com)
  • Ebola (EBOV) and Marburg (MARV) viruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period of 4-14 days. (sbir.gov)
  • No EBOV RNA was detected in any of the PCR-tested bat samples [and] attempts to demonstrate the presence of IgG antibodies against Ebola viruses were inconclusive (data not shown). (vectorsjournal.org)
  • ZMapp), anti-sense phosphorodiamidate morpholino oligomers (PMO AVI-6002), lipid nanoparticle small interfering RNA (LNP-siRNA: TKM-Ebola), and an EBOV glycoprotein-based vaccine using live-attenuated recombinant vesicular stomatitis virus (rVSV-EBOGP) or a chimpanzee adenovirus (rChAd-EBOGP)-based vector. (biomedcentral.com)
  • Flow chart of participants screened for the Ebola virus vaccine trial and seroprevalence study in a community affected by the 2014-2016 Ebola outbreak, Sierra Leone. (cdc.gov)
  • investigators stopped enrolling new subjects in January 2016, having failed to reach its enrollment goal of 200 due to the waning of the Ebola outbreak. (wikipedia.org)
  • View images depicting handwashing and personal protective equipment (PPE) protocols during Guinea's 2014-2016 Ebola epidemic. (cdc.gov)
  • Find photographs, oral histories, and documents from the 2014-2016 Ebola epidemic through Global Health Chronicles external icon , a CDC Museum/Emory University collaboration. (cdc.gov)
  • Learn more about the 2014-2016 Ebola outbreak in West Africa and while you're at it, explore what we know about all Ebola outbreaks from 1976 to present day. (cdc.gov)
  • Check out a timeline of Ebola cases during CDC's 2014-2016 response. (cdc.gov)
  • Explore the art that arose from the 2014-2016 Ebola outbreak. (cdc.gov)
  • ZMapp was administered under emergency use authorization to Ebola-infected patients during the 2014-2016 outbreak. (nih.gov)
  • Our knowledge gaps and the need for improved forecasting of zoonotic disease risk were starkly illustrated by the 2013-2016 Ebola outbreak, which was unprecedented in terms of size, financial cost, and geographical location 10 , 11 . (nature.com)
  • Between 2014 and 2016, West Africa endured an Ebola epidemic that was easily the largest and deadliest in history. (vectorsjournal.org)
  • Ebola virus (EBV) is a deadly virus that has resulted in a number of deaths during its outbreaks in Africa in 2014-2016 and 2018-2019. (intechopen.com)
  • Ebola virus, like the Marburg virus now alarming Angola, is a filovirus, a family of viruses that cause severe and frequently fatal hemorrhagic fevers. (sciencedaily.com)
  • The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. (nih.gov)
  • More recently, provocative studies have found high antibody seroprevalence to viruses such as Ebola, Marburg, and Lyssa viruses in multiple African countries, indicating the presence of a high number of undiagnosed cases every year, including high neutralizing titers of antibodies to rabies virus in 11% of a small cohort of asymptomatic Peruvians living in the Amazon with prior exposure to bats. (medscape.com)
  • CDC continues to research the virus and work with other countries to control outbreaks of Ebola. (cdc.gov)
  • Check out a visual representation of contact tracing pdf icon and its utility during Ebola outbreaks. (cdc.gov)
  • Explore a collection of outbreak responder stories from Ebola outbreaks of the past. (cdc.gov)
  • Ebola virus disease (EVD) was first identified in 1976, and since then there have been ~23 recognized outbreaks 12 , predominantly within central Africa. (nature.com)
  • Since it was discovered in 1976, Ebola virus has caused dozens of outbreaks, mostly in central and west Africa. (innovations-report.com)
  • Knowing that a response occurs at 14 days is important, they noted, since vaccines are often distributed only when Ebola outbreaks occur. (medpagetoday.com)
  • In the recurring, deadly Ebola outbreaks in parts of Africa, today's health workers now have at least some tools to fight the disease: vaccines. (weizmann-usa.org)
  • Although the mechanism is unclear, hiccups were noted in fatal cases of Ebola virus disease in both the 1976 and the 1995 outbreaks in the Democratic Republic of the Congo (DRC). (medscape.com)
  • ZMapp was discontinued in the 2018-19 Kivu Ebola epidemic. (wikipedia.org)
  • Hear Diana Toomer external icon share her experiences working for CDC-INFO during the 2014 West Africa Ebola epidemic. (cdc.gov)
  • Fogarty has launched a new program to help prepare institutions in countries most affected by the recent Ebola epidemic compete for research training support. (nih.gov)
  • mAb114 is a monoclonal antibody that was isolated from a survivor of the 1995 Ebola epidemic in the Democratic Republic of the Congo. (nih.gov)
  • "The severe Ebola virus disease epidemic occurring in West Africa stems from a single zoonotic transmission event to a 2 ‐ year ‐ old boy in Meliandou, Guinea . (vectorsjournal.org)
  • 13C6 specifically binds to glycoprotein associated with Ebola virus and can be potentially used in the. (bioscience-explained.org)
  • Inspect an electron microscopic image of the 1976 isolate of Ebola virus , as well as a digitally-colorized scanning electron microscope image of Ebola virus particles budding from African green monkey kidney cells. (cdc.gov)
  • But how can Ebola drugs be tested for efficacy if their use is restricted during the most widespread Ebola outbreak since 1976? (forbes.com)
  • [ 26 ] It is worth noting that in the 1976 Ebola outbreak, bleeding was seen in most cases, whereas in the 1995 Ebola outbreak, bleeding occurred in only half of the patients. (medscape.com)
  • Spike glycoprotein (PDB Id: 6VSB) of the coronavirus was selected and analysed using immune epitope database server for prediction of potential immunogenic B and T-cell epitopes. (ijpsonline.com)
  • Contagious human coronavirus (SARS-CoV-2) binds to the receptors of human host cells by transmembrane spike glycoprotein that makes homotrimers protruding from viral surface region[ 9 , 10 ]. (ijpsonline.com)
  • In addition to LCMV and Ebola virus we are also investigating MERS coronavirus. (dpz.eu)
  • Shortly after the DRC announced an outbreak of Ebola virus disease in August 2018, ZMapp was made available to Ebola patients under an expanded access or "compassionate use" framework. (nih.gov)
  • In 2014, during the largest ever outbreak of Ebola virus disease (EVD), clinical trials of candidate vaccines against EVD were conducted in the Region, resulting in a safe and highly effective vaccine.1 Achieving universal health coverage requires overcoming inequities in access to health interventions, and this, in part entails clinical trials of new or existing medicinal products, particularly those meant for poor populations. (who.int)
  • This vaccine is genetically engineered to express a glycoprotein from Zaire ebolavirus to provoke a neutralizing immune response. (medscape.com)
  • Nucleoside analogue inhibitors of the cell-encoded enzyme S-adenosylhomocysteine hydrolase (SAH) have been shown to inhibit Zaire ebolavirus replication in adult BALB/c mice infected with mouse-adapted Ebola virus. (medscape.com)
  • To recap, the ZMapp combination product of three, humanized antibodies against different parts of the Ebolavirus outer glycoprotein - which continues to be called a "secret serum" - was given to Dr. Kent Brantly and Nancy Writebol prior to their medivac journey from a hospital in Paynesville, Liberia, to the biosafety level-4 isolation ward in Atlanta's Emory University Hospital. (forbes.com)
  • In stark contrast Reston ebolavirus (RESTV) might be non-pathogenic for humans yet the underlying mechanisms determining pathogenicity for different Ebola viruses are not understood. (nih.gov)
  • I just think that it's really difficult without knowing facts," says Dr. Thomas Geisbert of the University of Texas, an Ebola vaccine researcher who has worked with most of the vaccines coming to market, in some capacity, over the years. (thedailybeast.com)
  • Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses an individual filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). The main concern with all replication-competent vaccines, including the rVSV filovirus GP vectors, is their safety. (nih.gov)
  • In recent years, vaccines and effective therapies for Ebola have been developed, but they are not widely available. (innovations-report.com)
  • Ebola monoclonal antibodies may interfere with immune response of live vaccines. (medscape.com)
  • Vaccines against Ebola have been administered to over 100,000 people to date, but they are barely out of the experimental stage. (weizmann-usa.org)
  • Dr. Ron Diskin of the Institute's Department of Structural Biology explains: "These vaccines - made by recombinant methods that attach an Ebola protein to a harmless virus - are hard to produce, and thus there is not enough of them to vaccinate an entire population. (weizmann-usa.org)
  • The 2014 West African Ebola outbreak is the largest Ebola outbreak ever documented, and the first recorded in the region. (wikipedia.org)
  • It binds to the glycoprotein cap of the virus. (wikipedia.org)
  • mAb114 binds to an extremely conserved region on the Ebola virus (specifically the Zaire virus species), thus blocking its interactions with a receptor on human cells. (nih.gov)
  • Investigators funded through the CETR program identified ZMapp's structure and how it binds to Ebola virus, and now they're using this knowledge to test next-generation antibodies for better binding and efficacy. (nih.gov)
  • NPC1 encodes the receptor that Ebola virus binds to, but CIITA was more mysterious. (the-scientist.com)
  • The p41 protein binds to proteases called cathepsins, preventing the enzymes from cleaving the Ebola glycoprotein, thus stopping the fusion of the virus with the endosome and the release of the viral genome into the cell, the team demonstrated. (the-scientist.com)
  • We generated a recombinant vesicular stomatitis virus encoding Ebola virus Makona variant GP 1,2 (rVSV-MAK-GP) and observed emergence of a T544I mutation in the Makona GP 1,2 gene during tissue culture passage in certain cell lines. (nau.edu)
  • Three vaccine regimens for Zaire Ebola virus disease (EVD) produced antibody responses in adults and children, according to the results of two randomized trials conducted in West Africa. (medpagetoday.com)
  • The infectious agent that caused the outbreak was a filovirus, the Zaire species of Ebola virus (sometimes called ZEBOV and sometimes just Ebola), which has a fatality rate of up to 90 percent ( Feldmann and Geisbert, 2011 ). (vectorsjournal.org)
  • Here, we analyzed NK cell phenotype and function in response to Ad26.ZEBOV, MVA-BN-Filo vaccination regimen and in response to in vitro Ebola glycoprotein stimulation of PBMCs isolated before and after vaccination.RESULTSWe show enhanced NK cell proliferation and activation after vaccination compared with baseline. (ox.ac.uk)
  • [ 3 ] In the Ring vaccination study, in which patients were vaccinated during the 2014 outbreak in the Republic of Guinea, results among the people who received the vaccine showed no Ebola cases were recorded 10 days or more after vaccination. (medscape.com)
  • 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. (who.int)
  • Furthermore, on the basic scientific level, the effects of vaccination on the immune system and how the immune response of vaccinated individuals compares with that of individuals who have survived Ebola infections was not known. (weizmann-usa.org)
  • A Weizmann Institute of Science lab recently joined forces with a research team in Cologne, Germany, to uncover the details of the molecular response that occurs in the immune system after vaccination against Ebola. (weizmann-usa.org)
  • There is no cure or specific treatment for the Ebola virus disease that is currently approved for market, although various experimental treatments are being developed. (wikipedia.org)
  • A distributed computing project, Outsmart Ebola Together, has been launched by World Community Grid in collaboration with the Scripps Research Institute to help find chemical compounds to fight the disease. (wikipedia.org)
  • Favipiravir (Avigan) is a broad-spectrum antiviral drug, used to treat influenza, which in a mouse model appears to be useful in treating Ebola disease. (wikipedia.org)
  • By quickly isolating the disease, CDC and other disease control organizations prevented the spread of the Ebola virus . (cdc.gov)
  • Learn more about the virus that causes Ebola and the global impact of the disease. (cdc.gov)
  • Explore prevention tips, contact tracing resources, and key facts with CDC's Disease of the Week ebola feature , then try your hand at a short quiz. (cdc.gov)
  • Patients who have died of Ebola virus disease should be buried promptly and with as little contact as possible. (medscape.com)
  • During the 1995 outbreak in Kikwit, DRC, human convalescent plasma was used to treat 8 patients with proven Ebola disease, and only 1 patient died. (medscape.com)
  • NIAID is conducting and funding research on several experimental Ebola treatments, with the goal of alleviating suffering and stopping the spread of disease. (nih.gov)
  • Results indicate the antibody cocktail was well-tolerated and showed promise, but there was insufficient data to determine definitively whether it is a better treatment for Ebola virus disease than supportive care alone. (nih.gov)
  • However, ZMapp is no longer being administered to Ebola virus disease patients in the DRC after the preliminary results of the PALM trial indicated mAb114 and REGN-EB3 are superior. (nih.gov)
  • The investigational antiviral agent GS-5734, also known as remdesivir, is being developed by Gilead as a treatment for Ebola virus disease. (nih.gov)
  • Remdesivir is no longer being administered to patients with Ebola virus disease in the DRC after the preliminary results of the PALM trial were announced. (nih.gov)
  • This novel approach provides a simple and efficient vaccine platform for Ebola disease prevention. (frontiersin.org)
  • Here, we develop modelling methods that capture elements of each of these factors, to predict the risk of Ebola virus disease (EVD) across time and space. (nature.com)
  • The technology, which uses so-called optical microring resonators, potentially could be developed into a rapid diagnostic test for the deadly Ebola virus disease, which kills up to 89% of infected people. (innovations-report.com)
  • Because no natural reservoir of Ebola has been identified, the relation between specific exposure to potential arthropod, animal, or plant vectors and disease remains unproven. (medscape.com)
  • UNITED NATIONS: With more than one million people affected by the current Ebola outbreak in West Africa, the WHO has warned that there is "no early end in sight" to the severe health crisis and called for "extraordinary measures" to stop the transmission of the disease. (blogspot.com)
  • Spike glycoprotein has two subunits, S1-responsible for its binding to host cell membrane receptors and S2-responsible for the fusion of viral and host cellular membrane[ 8 , 11 ]. (ijpsonline.com)
  • The spike glycoprotein sequence was retrieved from protein data bank (PDB) database. (ijpsonline.com)
  • Ebolaviruses have a surface glycoprotein (GP 1,2 ) that is required for virus attachment and entry into cells. (nau.edu)
  • Nonhuman primates were challenged on day 20 postimmunization with 1000 50% tissue culture infective dose of Ebola virus/H.sapiens-tc/GIN/2014/Makona-C07. (infectiousdiseaseadvisor.com)
  • However, it has been shown that levels of glycoprotein-binding antibodies strongly correlate with neutralizing antibody titers in nonhuman primates and humans," they added. (medpagetoday.com)
  • ZMapp is a combination of three chimeric monoclonal antibodies effective in Ebola-infected monkeys. (wikipedia.org)
  • After immunization, there was a robust induction of glycoprotein-specific antibody responses and the establishment of cytokine-producing, antigen-specific memory T-cell responses. (infectiousdiseaseadvisor.com)
  • By utilizing the favorable immune cell targeting of the Ebola glycoprotein, better foreign antigen presentation can be achieved. (nih.gov)
  • In the 1995 Ebola virus outbreak in Kikwit, DRC, tachypnea was the single most discriminating sign that separated survivors (none of whom had tachypnea) from patients who died (37% of whom had tachypnea). (medscape.com)
  • Ocular complications were reported in 3 (15%) of 20 survivors of the 1995 Ebola outbreak in the Democratic Republic of the Congo (DRC). (medscape.com)
  • Analysis of complete viral genomes collected from patients in western Africa indicated that this mutation was not found in Ebola virus clinical samples. (nau.edu)
  • With Ebola still tearing through West Africa, surely the last thing anyone wants to hear about it are setbacks in the search for a vaccine. (thedailybeast.com)
  • Lassa fe- Lassa virus in many more districts and states in en- ver is endemic in West Africa and has been reported demic countries of the West African sub-region and from Sierra Leone, Guinea, Liberia, and Nigeria4-7. (folkhalsomyndigheten.se)
  • Combinations of face envelope with T-shaped spikes measuring 7-10 key words such as Lassa fever and West Africa were nm and built with glycoprotein. (folkhalsomyndigheten.se)
  • 3D print an Ebola envelope glycoprotein through the National Institutes of Health 3D Print Exchange external icon . (cdc.gov)
  • NIAID is studying its ability to clear Ebola virus RNA from the semen of Ebola survivors in a study in Liberia known as PREVAIL 4 . (nih.gov)
  • History of admission and discharge from an Ebola Treatment Unit as registered by the Sierra Leone Association of Ebola Survivors (SLAES). (who.int)
  • Ebola virus reproduction in laboratory-grown cells is severely hampered by enzyme-inhibiting chemicals, and these chemicals deserve further study as possible treatments for Ebola virus infections in humans, report scientists supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). (sciencedaily.com)
  • This new research sheds light on the mechanism Ebola virus uses to enter cells," notes NIAID Director Anthony S. Fauci, M.D. "These findings raise the possibility of a broad-spectrum antiviral therapy that could be effective against multiple hemorrhagic fever viruses. (sciencedaily.com)
  • In November 2018, NIAID and the Democratic Republic of the Congo's National Institute for Biomedical Research (INRB) began a Phase 2/3 clinical trial testing multiple investigational Ebola therapies. (nih.gov)
  • Current diagnostic tests detect the virus's genetic material or a glycoprotein - a protein covered in sugar - produced by the virus. (innovations-report.com)
  • When the cells are exposed to an Ebola-mimicking virus, the p41-bound cathepsins are unable to cleave off the virus's glycoprotein, stopping it from fusing with the membrane and thus trapping it inside the endosome. (the-scientist.com)
  • In a cell where CD74 is not overexpressed (right), cathepsins cleave the virus's glycoproteins, enabling it to fuse with the side of the endosome and release its genetic material into the cytosol. (the-scientist.com)
  • The first step was to understand exactly how and where the antibodies bind to the viral glycoprotein (part of a virus's outer membrane) used in the vaccine, and just how such binding neutralizes the virus so effectively. (weizmann-usa.org)
  • 1993). The GP gene of ebolaviruses codes for the shorter secreted glycoprotein (sGP), while expression of the transmembrane full-length GP requires transcriptional editing of mRNA (Sanchez et al. (nuche.org)
  • Human LSECtin is an approximately 40 kDa, single-pass, type II transmembrane glycoprotein that is 293 amino acids (aa) in length. (rndsystems.com)
  • After adding these transposons to flasks of human cells, Bruchez introduced viruses engineered to express an Ebola glycoprotein, killing most of the cells. (the-scientist.com)
  • Electron microscopy showed that, in cells expressing p41 , the glycoprotein remained trapped inside the endosomes that housed the engineered viruses after they were internalized by the cell. (the-scientist.com)
  • In addition, LSECtin has the ability to bind to surface glycoproteins of enveloped viruses (3, 4). (rndsystems.com)
  • A total of five major Open Reading Frames (ORF) were found in COVID-19: the ORF 1a/b region coding replicase and other enzymes, the spike or S protein ORF, M or membrane glycoprotein ORF, E or small membrane protein ORF and the N or nucleocapsid ORF ( fig. 1 )[ 5 ]. (ijpsonline.com)
  • Pictured is a colorized scanning electron microscopic image that depicts Ebola virus particles budding from the surface of a cell. (innovations-report.com)
  • Advances in the preparation, detection, automation, and computational analysis (some of which garnered their developers a Nobel Prize in 2017) have made this latest version of the electron microscope able to reveal the 3D structure, practically down to the last atom, of an antibody bound to its target on the glycoprotein. (weizmann-usa.org)
  • Surface representations in grey and pink show the two distinct submits that make the trimeric Ebola spike complex. (weizmann-usa.org)
  • Smith and colleagues found that in rhesus macaques infected with a lethal dose of Ebola virus, treatment with interferon beta early after exposure led to a significant increase in survival time, though it did not reduce mortality significantly. (medscape.com)
  • When one specific cellular enzyme, cathepsin B, was inhibited, the infectivity of Ebola virus dropped to near zero. (sciencedaily.com)
  • Most widely publicized has been TKM-Ebola, a lipid nanoparticle, RNA-interference drug being developed by Vancouver-based, Tekmira Pharmaceuticals, together with a division of the Department of Defense. (forbes.com)
  • Firstly, the VFP sequence must achieve a set of native interactions required for (meta) stable folding within the globular ectodomains of the glycoprotein complexes. (tcdb.org)
  • Interaction of the viral glycoprotein (GP) with Toll-like receptor 4 (TLR4) leading to activation of NF_B signaling is responsible for this effect rather than differences in replication or blocking of immune signaling. (nih.gov)
  • These results demonstrate a correlation of pathogenicity and excessive MDM activation for different Ebola virus species. (nih.gov)
  • MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses," Science , 370:241-47, 2020. (the-scientist.com)
  • 2021). Ebola virus glycoprotein interacts with cholesterol to enhance membrane fusion and cell entry. (tcdb.org)
  • 2017). Ebola Virus Delta Peptide is a Viroporin. (tcdb.org)
  • Although transmission of Ebola virus to humans is not fully understood, it is thought to occur by exposure to infected animals and spread human-to-human from direct contact with blood or other bodily fluids, as well as indirect contact with environments contaminated by these fluids. (medpagetoday.com)
  • The scientists applied broad-spectrum enzyme inhibitors to mammalian cells before exposing them to Ebola virus. (sciencedaily.com)
  • While the source of Ebola is unknown, scientists do have some theories and suspect that bats are the natural reservoir for the virus. (cdc.gov)
  • The antibodies bind to three different regions of the glycoprotein of the Ebola virus, inhibiting viral replication. (nih.gov)